Smoldering Multiple Myeloma Clinical Trials

14 recruiting

Smoldering Multiple Myeloma Trials at a Glance

20 actively recruiting trials for smoldering multiple myeloma are listed on ClinicalTrialsFinder across 6 cities in 18 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Bari, Boston, and Pavia. Lead sponsors running smoldering multiple myeloma studies include University of Miami, University of Rochester, and Dana-Farber Cancer Institute.

Browse smoldering multiple myeloma trials by phase

Treatments under study

About Smoldering Multiple Myeloma Clinical Trials

Looking for clinical trials for Smoldering Multiple Myeloma? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Smoldering Multiple Myeloma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Smoldering Multiple Myeloma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Not Applicable

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
University of Miami120 enrolled1 locationNCT07446777
Recruiting

Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution

Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)Multiple Myeloma (MM)
Azienda USL Reggio Emilia - IRCCS60 enrolled4 locationsNCT07214324
Recruiting
Not Applicable

A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
Memorial Sloan Kettering Cancer Center180 enrolled8 locationsNCT05640843
Recruiting

Promoting Diagnosis and Management of AL in Italy (ProDigALIty)

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple MyelomaAL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia760 enrolled4 locationsNCT06383143
Recruiting
Phase 2

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled20 locationsNCT06140524
Recruiting

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
University of Miami1,000 enrolled1 locationNCT05361694
Recruiting
Not Applicable

A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma

Smoldering Multiple Myeloma (SMM)
Ciceri Fabio62 enrolled5 locationsNCT07069751
Recruiting

Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

Smoldering Multiple Myeloma
University of Utah100 enrolled1 locationNCT06212323
Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Smoldering Multiple MyelomaMyelodysplastic SyndromesWaldenstrom Macroglobulinemia+5 more
Dana-Farber Cancer Institute10,000 enrolled7 locationsNCT02269592
Recruiting

CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

Multiple MyelomaSmoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)+2 more
Wake Forest University Health Sciences1,665 enrolled1 locationNCT06644625
Recruiting

European Myeloma Network (EMN) Sample Project

Multiple MyelomaSmoldering Multiple MyelomaPlasma Cell Leukemia+2 more
European Myeloma Network B.V.6,000 enrolled41 locationsNCT06237803
Recruiting

Registry for Adults With Plasma Cell Disorders (PCD's)

Multiple MyelomaAmyloidosisSmoldering Multiple Myeloma+6 more
UNC Lineberger Comprehensive Cancer Center2,000 enrolled1 locationNCT03717844
Recruiting

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Smoldering Multiple Myeloma
Tufts Medical Center400 enrolled13 locationsNCT06365060
Recruiting
Phase 1Phase 2

The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

Multiple MyelomaSmoldering Multiple Myeloma
Oslo University Hospital20 enrolled1 locationNCT05841550
Recruiting

Whole Body MRI in Oncology

Advanced Breast CancerAdvanced Prostate CancerMultiple Myeloma+3 more
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1,000 enrolled3 locationsNCT06895291
Recruiting
Phase 2

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma
University of Rochester15 enrolled1 locationNCT05597345
Recruiting
Phase 2

Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma

High Risk Smoldering Multiple Myeloma
PETHEMA Foundation20 enrolled1 locationNCT06574126
Recruiting
Phase 2

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma
Stichting European Myeloma Network50 enrolled25 locationsNCT06183489
Recruiting
Phase 2

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

Prostate CancerMultiple MyelomaMonoclonal Gammopathy of Undetermined Significance+1 more
University of Rochester40 enrolled1 locationNCT04731844
Recruiting

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

Multiple MyelomaAmyloidosisSmoldering Multiple Myeloma+9 more
Peking University First Hospital2,000 enrolled1 locationNCT05283993